FDA Will Announce Three Sentinel Development Collaborations In Coming Year
Executive Summary
The collaborations will mark a new phase in the agency’s development of Sentinel, a national medical product surveillance initiative using a distributed network of electronic databases.
You may also be interested in...
Mini-Sentinel Expanding Drug Safety Efforts To Prospective Surveillance
The effort will complement the FDA-funded project’s existing ability to retrospectively measure exposure to products and then analyze specific adverse outcomes.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.